Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. KalVista Pharmaceuticals Inc shares valued at $24,272 were sold by Audhya Paul K. on May 23 ’25. At $11.31 per share, Audhya Paul K. sold 2,146 shares. The insider’s holdings dropped to 113,026 shares worth approximately $1.53 million following the completion of this transaction.
Also, Yea Christopher sold 1,926 shares, netting a total of over 21,782 in proceeds. Following the sale of shares at $11.31 each, the insider now holds 98,189 shares.
Before that, Audhya Paul K. had sold 2,689 shares from its account. In a trade valued at $31,933, the CHIEF MEDICAL OFFICER traded KalVista Pharmaceuticals Inc shares for $11.88 each. Upon closing the transaction, the insider’s holdings decreased to 2,689 shares, worth approximately $1.49 million.
As published in their initiating research note from JMP Securities on January 31, 2025, KalVista Pharmaceuticals Inc [KALV] has been a Mkt outperform and the price target has been revised to $19. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in early January. As of December 18, 2024, BofA Securities has initiated its “Buy” rating for KALV. Earlier on June 15, 2020, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for KALV stock.
Analyzing KALV Stock Performance
During the last five days, there has been a surge of approximately 18.77%. Over the course of the year, KalVista Pharmaceuticals Inc shares have jumped approximately 59.86%. Shares of the company reached a 52-week high of $14.00 on 04/30/25 and a 52-week low of $7.30 on 01/13/25.
Support And Resistance Levels for KalVista Pharmaceuticals Inc (KALV)
According to the 24-hour chart, there is a support level at 13.33, which, if violated, would cause prices to drop to 13.12. In the upper region, resistance lies at 13.66. The next price resistance is at 13.78. RSI (Relative Strength Index) is 65.54 on the 14-day chart, showing neutral technical sentiment.
